Newsroom

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

1 min read

Selexis Announces Expansion of R&D License Agreement with Amgen

Feb 20, 2014 1:20:46 PM

Expansion to Include the Selexis SURE CHO-M Cell Line™

Geneva, Switzerland (PRNEWSWIRE) February 20, 2013 – Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line™ for research and development. Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D.

“Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable,” said Igor Fisch, PhD, President, and CEO of Selexis. “Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently. This current agreement is built on the long-standing relationship between our two companies since 2004.”

Topics: 2014

Featured